News
Johnson & Johnson’s Psoriasis Drug ICOTYDE Shows Sustained Skin Clearance
Johnson & Johnson’s Phase 3 study of ICOTYDE showed sustained treatment responses in adults and adolescents with plaque psoriasis, with at least 70% achieving clear or almost clear skin from Week 64 through Week 112.
imphoenix82
- October 12, 2026
- 0 Comments
- 465 Views
-
